Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rat ...

Endovascular thrombectomy (EVT) does not lead to better outcomes at 90 days compared with usual care or best medical t ...